Background: Suboptimal medication adherence among individuals with diabetes presents a significant challenge in low-income nations. Growing evidence demonstrates the effectiveness of text messaging interventions to enhance medication adherence. This study assesses the intention to use Short Messaging Service (SMS) based reminder services in promoting drug adherence among diabetic patients and associated factors in Addis Ababa, Ethiopia.
Methods: An institution-based cross-sectional study was conducted from February 06, 2023, to March 27, 2023, in Addis Ababa, Ethiopia. A sample of 351 patients was selected using systematic random sampling. Structured questionnaires were used for data collection. Binary and multivariable logistic regression models were used to analyze the association between intention to use SMS reminders to promote drug adherence among individuals with diabetes and related factors.
Results: A total of 333 respondents, with a 94.87% response rate, were interviewed for this study. The majority of respondents, 66.4 % (95% CI [61.9-71.2]), expressed an intention to use SMS-based reminder services to promote their drug adherence. Age < 45 years (AOR = 5.73, 95% CI [2.07-15.73]), higher educational level (AOR = 3.03, 95% CI [1.16-7.90]), type of diabetes (AOR = 3.71, 95% CI [1.16-7.90]), oral medication users (AOR = 2.99, 95% CI [1.42-6.32]), SMS as a preferred medium for communication (AOR = 2.86, 95% CI [1.17-7.00]) were deemed to be important variables linked to intention to use SMS reminders to promote drug adherence among individuals with diabetes.
Conclusion: The findings suggest the majority of individuals with diabetes have intention to use SMS reminders to enhance adherence. This result indicates the potential for utilization of SMS reminders to enhance adherence to diabetic medications. Furthermore, the findings highlight the importance of tailored interventions that take into account patient characteristics and preferences as factors that influence intention when designing such an intervention.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568812 | PMC |
| http://dx.doi.org/10.7717/peerj.18297 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of compliance with tetracycline eye ointment treatment to accelerate the elimination of trachoma in Yobe State, Nigeria.
Int Health
March 2025
Department of Ophthalmology, 930003, University of Jos, Plateau State, Nigeria.
Background: Trachoma, a neglected tropical disease, remains a significant public health concern in many regions, particularly in sub-Saharan Africa and in Yobe State, Nigeria. One approach for elimination involves administering tetracycline eye ointment (TEO) to children <6 months of age as part of annual mass drug administration (MDA), aligning with the World Health Organization's 'A' component of the SAFE (Surgery, Antibiotics, Facial hygiene and Environmental sanitation) strategy for elimination of trachoma as a public health problem. However, suboptimal compliance rates in affected populations pose challenges, potentially serving as a reservoir for reinfection and hindering progress toward trachoma elimination.
View Article and Find Full Text PDFEffectiveness of Switching from Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in Patients with COPD in a Real-World Setting in Japan.
Int J Chron Obstruct Pulmon Dis
March 2025
Real World Data Analytics, Japan Development, GSK, Tokyo, Japan.
Purpose: Following the relatively recent introduction of single-inhaler triple therapies in Japan, this study compared the effectiveness of switching from multiple-inhaler triple therapy (MITT) to once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) by investigating COPD exacerbations and adherence among patients with chronic obstructive pulmonary disease (COPD) in Japan.
Methods: This retrospective, pre-post cohort study using the Medical Data Vision Co. Ltd database identified patients with ≥1 inpatient diagnosis and/or ≥2 outpatient diagnoses of COPD at age ≥40 years prior to the index date (first/earliest date of single-inhaler FF/UMEC/VI initiation from May 1, 2019-February 28, 2022, following a switch from MITT).
High-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated approach.
Front Pharmacol
February 2025
Department of Drug Discovery and Development, GenFleet Therapeutics (Shanghai) Inc., Shanghai, China.
Introduction: The cytochrome P450 enzyme 3A4 (CYP3A4) mediates numerous drug-drug interactions (DDIs) by inducing the metabolism of co-administered drugs, which can result in reduced therapeutic efficacy or increased toxicity. This study developed and validated a Physiologically Based Pharmacokinetic (PBPK) model to predict CYP3A4 induction-mediated DDIs, focusing on the early stages of clinical drug development.
Methods: The PBPK model for rifampicin, a potent CYP3A4 inducer, was developed and validated using human pharmacokinetic data.
A Multi-Method Study to Develop and Pilot Test an Interprofessional Transitional Care Model for Frail Older Adults - AdvantAGE.
J Adv Nurs
March 2025
Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
Aim(s): To develop and pilot test the AdvantAGE transitional care model at a Swiss geriatric hospital.
Design: Multi-method design.
Methods: The study progressed in three stages from January 2021 to December 2023: (1) contextual analysis using the Consolidated Framework for Implementation Research, incorporating qualitative interviews, (2) development and pilot testing of transitional care interventions on three acute geriatric wards using a descriptive explorative study design and (3) development and validation of a logic model using an iterative approach involving project interest groups and researchers.
Spray-Dried Inhalable Favipiravir Dry Powder Formulation for Influenza Therapy: Preparation and In vivo Evaluation.
Curr Drug Deliv
March 2025
School of Public Health and Health Management, Gannan Medical University, Ganzhou 341000, People's Republic of China.
Background: Influenza, a seasonal infectious disease, has consistently posed a formidable challenge to global health in recent years. Favipiravir, an RNA-dependent RNA polymerase inhibitor, serves as an anti-influenza medication, currently administered solely in oral form for clinical use. However, achieving an effective therapeutic outcome often necessitates high oral doses, which can be accompanied by adverse effects and suboptimal patient adherence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!